From: Novel biomarkers for monitoring and management of hepatocellular carcinoma
 | Name | Biomarker role | Refs. |
---|---|---|---|
1 | MALAT1 | Regulation of miRNAs (miR-204, miR-143-3p, miR-30a-5p, miR-200a, miR-124-3p, miR-195, and miR-22) involving in EMT | [139] |
2 | CTBP | Detection of cirrhotic HCC | [140] |
3 | LINC00152, XLOC014172, RP11-160H22.5 + AFP | Differentiating HCC patients from those with cirrhosis, chronic hepatitis, and normal individuals | [141] |
4 | Linc00974 | Elevated serum level in HCC patients | [142] |
5 | miRNAs miR-21, miR-199, and miR-122 | Upregulation in HCC samples | |
6 | miR-145, miR-29a, miR-133a, miR-143, miR-505 miR-29c, and miR-192 | Enhanced accuracy | [151] |
7 | miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801 | HCC detection among healthy individuals or cirrhotic patients | [152] |
8 | miR-6885-5p, miR-663a, miR-320b, miR-4448, miR-4749-5p, miR-6724-5p, miR-6877-5p, andmiR-4651 | Early stage detection of HCC | [132] |
11 | miR-4651 | Poor outcome | [155] |
12 | miR-1, miR-122, miR-26a, miR-29a, and miR-223-3p, miR-155, miR-96, and miR-193-5p | Poor outcome | [156] |
13 | miR-424-5p and miR-101-3p, miR-128, miR-139-5p, miR-382-5p, and miR-410 | Overall survival | [157] |
14 | miR-1246, miR-500 | Predicting early relapse after surgery | |
15 | miR-122, miR-26a, miR-2 | Prognostic indicators | [160] |
16 | miR-645, miR-200a, miR-122, miR-125b, miR-374b, miR-107, miR-15b, miR-320, and miR-30a | Overall survival | [163] |